EIPICO reports 17% y-o-y revenues decline to EGP 1.46bn in H1 2020
Pharmaceutical company underperformed on market, reporting aggressive 31% decline in retail sales
EIPICO postpones development plans due to US dollar shortage
The delayed development plans include recently announced new activities due to directing…
